Blindness News and Research

RSS

USC to develop stem cell-based treatment for age-related macular degeneration with CIRM grant

Physician-researchers at the University of Southern California (USC) received a nearly $16 million grant from the California Institute of Regenerative Medicine (CIRM) to fund the development of a stem cell-based treatment for age-related macular degeneration, the leading cause of vision loss and blindness among the elderly.

29 Oct 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.

29 Oct 2009

USC researchers receive grant to develop stem cell-based treatment for age-related macular degeneration

29 Oct 2009

Roche discloses the results of first Phase III clinical study using Taspoglutide

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research.

29 Oct 2009

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ - oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO).

27 Oct 2009

Study shows gene therapy can restore vision to children with Leber congenital amaurosis

Results from a breakthrough study, conducted by researchers at The Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania School of Medicine, show that gene therapy has restored significant vision in five children and seven adults who were previously blind.

27 Oct 2009

Implantation of blue light-filtering intraocular lens increases nutritional component of the eye

Results of an important new study show that implantation of blue light-filtering intraocular lens (IOLs) at the time of cataract surgery increases a nutritional component of the eye, which may afford protection against the development and/or progression of age-related macular degeneration (AMD).

27 Oct 2009

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T. Flynn, MD, Columbia University School of Medicine, discussing the ever-tougher challenges Eye M.D.s face in caring for the vision of the tiniest premature babies; and a report by Bradford W. Lee, MD, Stanford University School of Medicine, on barriers to glaucoma follow-up as perceived by patients in an urban, culturally diverse clinic.

26 Oct 2009

Saving sight in premature babies: The past, present and future of ROP treatment

26 Oct 2009

Gene therapy may help improve congenital blindness in children

Born with a retinal disease that made him legally blind, and would eventually leave him totally sightless, the nine-year-old boy used to sit in the back of the classroom, relying on the large print on an electronic screen and assisted by teacher aides. Now, after a single injection of genes that produce light-sensitive pigments in the back of his eye, he sits in front with classmates and participates in class without extra help. In the playground, he joins his classmates in playing his first game of softball.

26 Oct 2009

Vision loss after non-ocular surgery is rare but potentially devastating

Vision loss after non-ocular surgery is a rare but potentially devastating surgical complication that is usually the result of cortical blindness, ischemic optic neuropathy or retinal vascular occlusion. Due to its rare and unexpected occurrence, the origin of perioperative vision loss (POVL) is poorly understood.

26 Oct 2009

Potentia Pharmaceuticals and Alcon Research sign license and purchase option agreements

Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.

24 Oct 2009

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras

The ARVO Foundation for Eye Research (AFER) and Pfizer Ophthalmics are pleased to announce a series of awards named in honor of Carl B. Camras, MD. Up to three awards of $10,000 each will be presented annually for a period of 10 years to early career researchers.

24 Oct 2009

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension.

22 Oct 2009

People in developing countries spend 90% of all medical expenditures for diabetes care

Type 2 diabetes is often seen as a condition affecting older, unproductive adults in wealthy countries. However, the reality is that 70% of people with diabetes now live in low and middle-income countries and the economic impact of diabetes is much greater in poorer countries.

22 Oct 2009

New study suggests potential treatment for blindsight patients

Although we assume we can see everything in our field of vision, the brain actually picks and chooses the stimuli that come into our consciousness. A new study in the Association for Research in Vision and Ophthalmology's Journal of Vision reveals that our brains can be trained to consciously see stimuli that would normally be invisible.

22 Oct 2009

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

Electronic eye implant mimics human retina; restores partial vision

A 50-year-old New York woman who was diagnosed with a progressive blinding disease at age 13 was implanted with an experimental electronic eye implant that has partially restored her vision. A team led by Dr. Lucian V. Del Priore at NewYork-Presbyterian Hospital/Columbia University Medical Center performed the June 26 surgery -- the first case of its kind in New York.

22 Oct 2009

Blindness News and Research

USC to develop stem cell-based treatment for age-related macular degeneration with CIRM grant

Promedior granted European Orphan Medicinal Product Designation for PRM-151

USC researchers receive grant to develop stem cell-based treatment for age-related macular degeneration

Roche discloses the results of first Phase III clinical study using Taspoglutide

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

LX211 may become the first approved oral treatment for modifying the course of uveitis

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

Study shows gene therapy can restore vision to children with Leber congenital amaurosis

Implantation of blue light-filtering intraocular lens increases nutritional component of the eye

AAO-PAAO meeting discusses tougher challenges of treating premature babies' vision

Saving sight in premature babies: The past, present and future of ROP treatment

Gene therapy may help improve congenital blindness in children

Vision loss after non-ocular surgery is rare but potentially devastating

Potentia Pharmaceuticals and Alcon Research sign license and purchase option agreements

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

People in developing countries spend 90% of all medical expenditures for diabetes care

New study suggests potential treatment for blindsight patients

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Electronic eye implant mimics human retina; restores partial vision

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News